Stockscreener 앱 받기
3.42
13.62%
0.41
시간 외 거래:
3.35
-0.07
-2.05%
전일 마감가:
$3.01
열려 있는:
$3.06
하루 거래량:
5.82M
Relative Volume:
1.18
시가총액:
$898.21M
수익:
$194.75M
순이익/손실:
$-51.26M
주가수익비율:
-12.21
EPS:
-0.28
순현금흐름:
$-23.38M
1주 성능:
-8.06%
1개월 성능:
-7.82%
6개월 성능:
+59.81%
1년 성능:
+187.39%
1일 변동 폭
$3.03
$3.42
1주일 범위
$2.92
$3.79
52주 변동 폭
$1.11
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
명칭
Akebia Therapeutics Inc
전화
617-871-2098
주소
245 FIRST STREET, CAMBRIDGE, MA
AKBA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
3.42 | 994.08M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
147.35 | 64.93B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.44 | 45.07B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.54 | 41.53B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.37 | 18.37B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.50 | 13.68B | 2.99B | 1.21B | 1.13B | 25.06 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-04 | 재개 | H.C. Wainwright | Buy |
| 2025-04-28 | 개시 | Leerink Partners | Outperform |
| 2025-04-01 | 개시 | Jefferies | Buy |
| 2023-11-29 | 재개 | BTIG Research | Buy |
| 2023-08-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Needham | Buy → Hold |
| 2022-03-31 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-14 | 재확인 | Needham | Buy |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-11 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-02 | 개시 | JP Morgan | Overweight |
| 2019-03-20 | 개시 | Citigroup | Neutral |
| 2018-09-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2018-08-10 | 재확인 | Needham | Buy |
| 2018-06-06 | 재확인 | H.C. Wainwright | Buy |
| 2017-12-19 | 개시 | Piper Jaffray | Overweight |
| 2017-12-07 | 개시 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | Needham | Buy |
| 2016-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2016-12-20 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-15 | 개시 | Aegis Capital | Buy |
| 2016-09-29 | 개시 | Brean Capital | Buy |
| 2016-03-16 | 재확인 | Needham | Buy |
| 2016-01-21 | 개시 | Credit Suisse | Neutral |
모두보기
Akebia Therapeutics Inc 주식(AKBA)의 최신 뉴스
The Akebia Therapeutics, Inc. (NASDAQ:AKBA) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Is Akebia Therapeutics (NASDAQ:AKBA) A Risky Investment? - simplywall.st
How moving averages guide Akebia Therapeutics Inc. tradingIntraday Signal Forecast for Fast Traders - Newser
Identifying reversal signals in Akebia Therapeutics Inc.Free Optimized Watchlist With Daily Adjustments - Newser
What’s next for Akebia Therapeutics Inc. stock priceFree Growth Based Stock Signal Screener - Newser
Akebia outlines access to over 275,000 dialysis patients for Vafseo in Q4 as DaVita pilot launches - MSN
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q2 2025 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics Second Quarter 2025 Earnings: EPS: US$0.001 (vs US$0.041 loss in 2Q 2024) - Yahoo Finance
Akebia Therapeutics Inc. stock trend outlook and recovery pathAsset Growth Pattern and Return Summary - Newser
What does recent volatility data suggest for Akebia Therapeutics Inc.Free Oversold Bounce Stock Play Ideas - Newser
Akebia Therapeutics Reports Strong Q2 2025 Growth - The Globe and Mail
Using Bollinger Bands to evaluate Akebia Therapeutics Inc.Trend Following Ideas with Volume Confirmation - Newser
Is Akebia Therapeutics Inc. reversing from oversold territoryFree Real Profit Trade Plan Suggestions - Newser
Akebia Therapeutics (AKBA.O) Surges 9.14% — No Technical Signals Fired, But Why? - AInvest
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of “Buy” by Analysts - Defense World
Akebia (AKBA) Prepares for Q2 Earnings Announcement - GuruFocus
Akebia Therapeutics Inc (AKBA) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Growth Initiatives - GuruFocus
Akebia's Q2 2025 Earnings Call: Unpacking Contradictions in Vafseo Trends, Auryxia Revenue, and FDA Strategies - AInvest
Akebia (AKBA) Q2 Revenue Jumps 43% - AOL.com
Akebia Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Akebia Therapeutics Inc (AKBA) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Earnings call transcript: Akebia Ther Q2 2025 earnings miss, stock drops By Investing.com - Investing.com Canada
Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2 - Yahoo Finance
Akebia Therapeutics, Inc. SEC 10-Q Report - TradingView
Akebia Therapeutics Q2 revenue smashes expectations - MarketScreener
Akebia Therapeutics Inc Q2 2025 Earnings: Revenue Surges to $62. - GuruFocus
Akebia reports Q2 EPS 0c vs (4c) last year - TipRanks
Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference - GlobeNewswire
Akebia Q2 2025 Earnings Preview - MSN
Akebia Therapeutics CEO to Discuss Kidney Disease Innovations at Major Growth Conference - Stock Titan
Chart based exit strategy for Akebia Therapeutics Inc.Market Downturn Defense Strategy Analysis - Newser
Akebia Therapeutics Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees - MSN
Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT - MSN
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization - GlobeNewswire
Price momentum metrics for Akebia Therapeutics Inc. explainedFree Alpha Focused Technical Trade Signals - Newser
Is it the right time to buy Akebia Therapeutics Inc. stockCapitalize on high-growth stocks early - Jammu Links News
What are the technical indicators suggesting about Akebia Therapeutics Inc.Invest confidently with real-time data analysis - Jammu Links News
What are analysts’ price targets for Akebia Therapeutics Inc. in the next 12 monthsInvest confidently with expert support - Jammu Links News
What institutional investors are buying Akebia Therapeutics Inc. stockBuild a portfolio that outperforms consistently - Jammu Links News
When is Akebia Therapeutics Inc. stock expected to show significant growthUnlock high-yield investment opportunities - Jammu Links News
How Akebia Therapeutics Inc. stock performs during market volatilityFree Entry Zone Strategy for Consistent Profit - Newser
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics Awards $880K Worth of Stock Options in Strategic New Employee Package - Stock Titan
Order Book Volume Tilts Bullish on Akebia Therapeutics Inc.Entry Zone Strategy for Consistent Profit Shared - metal.it
Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year? - Yahoo Finance
Would Akebia Therapeutics (NASDAQ:AKBA) Be Better Off With Less Debt? - 富途牛牛
Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights - 富途牛牛
Should I hold or sell Akebia Therapeutics Inc. stock in 2025Market Forecast Opportunities For Beginners - Jammu Links News
Akebia Therapeutics Inc (AKBA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.43%
0.47%
자본화:
|
볼륨(24시간):